QUB

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

Retrieved on: 
Wednesday, October 27, 2021
Safety, Donnelly (surname), Compliance, Research, Academy, CSE, Patient, QUB, FDA, Holding, Infection, OTCQB, Ketamine, Doctor of Philosophy, BBSRC, Mental health, CEO, Trial of the century, Pharmaceutics, GLOBE, Pharmacy, Vaccine, Pharmaceutical industry

TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce the appointment of Professor Ryan Donnelly, a world leader in the research and development of microneedle delivery technologies, as scientific and technical advisor for PharmaThers microneedle patch delivery programs involving controlled-substances such as ketamine and compounds treating infectious diseases.

Key Points: 
  • TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce the appointment of Professor Ryan Donnelly, a world leader in the research and development of microneedle delivery technologies, as scientific and technical advisor for PharmaThers microneedle patch delivery programs involving controlled-substances such as ketamine and compounds treating infectious diseases.
  • Professor Donnelly's lab successfully completed research and published a paper titled Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery.
  • He is a leading expert and researcher in the field of transdermal delivery with a primary focus on microneedle drug delivery and its applications on improving therapeutic outcomes for patients.
  • Professor Ryan Donnelly commented, "I am delighted to expand my role with PharmaTher in the research, development and manufacturing of a next generation microneedle patch for the intradermal delivery of controlled-substances and compounds to treat infectious diseases.

Quebecor unveils QUB, its new consolidated content platform

Retrieved on: 
Wednesday, September 15, 2021
TVA, Technology, TVA Sports, Digital recording, Qubi, MONTRAL, Digital, Vidéotron, Industry, QUB, Radio, History, News, Music, Mobile phone

Designed and developed in Qubec by Quebecor's NumriQ team, QUB is a new platform that brings all of Quebecor's news and entertainment content together in one place.

Key Points: 
  • Designed and developed in Qubec by Quebecor's NumriQ team, QUB is a new platform that brings all of Quebecor's news and entertainment content together in one place.
  • QUB will serve as a content aggregator while providing a superior browsing experience and recommendations to increase discoverability.
  • "Quebecor has always been able to anticipate market demand," says Pierre Karl Pladeau, President and Chief Executive Officer of Quebecor.
  • The vast majority of the content is free, with the exception of the QUB musique music streaming platform and Vrai, Videotron's new subscription service dedicated to exclusive unscripted specialty content.